27 Jan 2016 --- Lonza have reported that 2015 was a successful year, on a financial and an operational level, with both segments – Specialty Ingredients and Pharma&Biotech – contributing to the strong results. Strong sales growth over 2014 in reported currency of 4.5% (a growth of 5.7% in constant exchange rates, CER) resulted in sales of CHF 3.80 billion.Each segment had double-digit CORE EBIT growth in CER, which led to an overall growth of 10.3% in reported currency (+12.0% in CER) to CHF 524 million.
